Another phase Ib trial evaluated the possibility of combination of nivolumab and ceritinib and subsequently showed a potent efficacy (ORR reaching up to 83%) with increasing toxicity in the treatment of naïve ALK‐rearranged NSCLC.199. Here, ALK is linked to non-small cell lung carcinoma.